Q-omics provides the consensus-scored MIRLET7A1HG profile across patient tissues and cancer cell-line models. MIRLET7A1HG expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIRLET7A1HG is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, MIRLET7A1HG RNA expression shows 17,626 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, LUAD, and UVM as cancer lineages where MIRLET7A1HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIRLET7A1HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIRLET7A1HG survival associations across molecular data types. MIRLET7A1HG RNA expression shows survival associations in the most cancer types (29). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIRLET7A1HG RNA expression–survival associations across cancer types. High MIRLET7A1HG expression shows unfavorable associations in CESC, UVM and MESO, but favorable associations in PAAD, UCS and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for MIRLET7A1HG RNA expression.
This table summarizes MIRLET7A1HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIRLET7A1HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIRLET7A1HG shows lower tumor expression in LUAD, KICH, UCEC, BRCA, LUSC and COAD. The LUAD box plot shows higher MIRLET7A1HG RNA expression in normal versus tumor tissue (log2 FC = −0.726, t-test p = .001).
This table shows molecular features associated with MIRLET7A1HG in patient tissues and cancer cell lines. In patient samples, MIRLET7A1HG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
